BL20-MMAE is an antibody-drug conjugate targeting ROR1, which is formed by conjugating an anti-ROR1 antibody with the Auristatin payload MMAE via a BL20 linker.

BL-1021 is an orally active ion channel blocker. BL-1021 significantly reduces symptoms of neuropathic pain without noticeable sedation or cardiac arrhythmias. BL-1021 can be used in the research of acute and chronic pain.

BKT300 is a potent and selective protein regulator of cytokinesis 1 (PRC1) inhibitor. BKT300 inhibits PRC1 dephosphorylation at T481, disrupts actin and microtubule formation, induces G2/M cell cycle arrest, triggers mitotic catastrophe, and promotes apoptosis, thereby inhibiting proliferation and migration of acute myeloid leukemia (AML) cells while sparing normal cells. BKT300 inhibits tumor growth in mouse xenograft AML models. BKT300 can be used for the research of AML[1].

BKI 1708 is a potent and orally active calcium-dependent protein kinase 1 (CDPK1) inhibitor (IC50 = 0.7 nM). BKI 1708 exhibits potent activity against Neospora (IC50 = 481 nM) and Toxoplasma (IC50 = 122 nM). BKI-1708 induces the formation of multinucleated complexes. BKI-1708 efficiently inhibits vertical transmission of both parasites and increases pup survival in mice.

Bis-Mal-Lysine-PEG4-DBCO (CGBS-13) is a linker for AOC drugs and can be used to synthesize AOC drugs that inhibit DMPK gene expression.

Bisdisulizole disodium is an organic chromophore with large near UV absorption cross section. Solutions of Bisdisulizole disodium dissolved in polar solvents show a strong, broad UV absorption feature centered at 340 nm.

Bilirubin ditaurine (BR-DT) is a mimetic compound of conjugated bilirubin. Bilirubin ditaurine can completely prevent the oxidation of phosphatidylcholine induced by reactive oxygen species in multilayer liposomes or micelles. Bilirubin ditaurine does not significantly decompose 18:2-OOH on its own, but it can greatly accelerate the decomposition of 18:2-OOH catalyzed by copper ions. Bilirubin ditaurine can be used to study the detoxification effect of conjugated bilirubin.

BILA 1906 BS is a HIV protease inhibitor. BILA 1906 BS prevents HIV-1 replication via inhibition of viral protease-mediated cleavage of Gag and Gag-Pol polyprotein precursors during virion maturation. BILA 1906 BS blocks maturation of p24 proteins in wild-type HIV-1, impairing polyprotein processing and viral maturation. BILA 1906 BS can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection.

BI-135585 hydrate is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor with an IC50 of 13 nM. BI-135585 hydrate exhibits >1000-fold selectivity over other hydroxysteroid dehydrogenases. BI-135585 hydrate can be used for type 2 diabetes research.

BF-175 is a selective SIRT1 agonist. BF175 increases SIRT1-mediated activation of PGC1-α, induces Apoptosis, induces Autophagy and inhibits SREBP activity. BF-175 protects against high glucose-mediated mitochondrial injury. BF-175 attenuates diabetic kidney disease progression. BF175 inhibits endometrial carcinoma.

BET-IN-29 (Compound 1) is a bromodomain and the terminal motif (BET) inhibitor. BET-IN-29 can be used for the study of cancer, inflammation, metabolism, neurological diseases, and infectious diseases.

Betamethasone succinate (NSSL-BMS) is a nano-formulation that can cross the blood-brain barrier. Betamethasone succinate is prepared by encapsulating the Betamethasone semi-succinate in PEG-liposomes. Betamethasone succinate utilizes the enhanced permeation and retention effects of liposomes to target and deliver the potent glucocorticoid to the inflammatory sites. Betamethasone succinate inhibits the secretion of pro-inflammatory cytokines (such as TNF-α and IL-6) while maintaining the level of anti-inflammatory cytokine TGF-β. Betamethasone succinate can be used in the research of arthritis and cerebral malaria.

Beta-alanyl-L-arginine (β-Alanyl-L-arginine) is an intestinal microbial metabolite. Beta-alanyl-L-arginine can be used for the study of schizophrenia.

Benzyl m-hydroxycarbanilate (Compound 9) is a biologically active chemical substance and also an intermediate.

Benzobarbital is an active low-toxicity inductor of the liver monooxygenase system. Benzobarbital raises cytochrome P-450 concentration. Benzobarbital can be used in the research of post-ischemic liver disease.

Benzazepinoquinoline-spermine (Compound PA-3) is an efficient pre-miR-372 complexing agent, and it can specifically inhibit its processing mediated by Dicer. Its IC₅₀ value is 0.58 μM. Benzazepinoquinoline-spermine has a strong affinity for pre-miR-372, with a KD value of 0.11 μM. Benzazepinoquinoline-spermine also shows high activity against pre-miR-373 (IC₅₀ = 0.29 μM), but significantly reduced inhibitory activity against pre-miR-17, pre-miR-21, and pre-miR-155 (IC₅₀ being 0.84 μM, 1.43 μM, and 1.07 μM respectively). Benzazepinoquinoline-spermine can be used for cancer research.

Bentioflumin is a fluoroalkylthiobenzene acaricide with excellent leaf penetration, and its control validity period against mites exceeds 25 days. Bentioflumin can be used in studies related to mite infestation.

Belotecan-GFGG is an intermediate. Belotecan-GFGG can be used to synthesize the peptide conjugate MI-6PEG-GGFG-Belotecan. Belotecan-GFGG can be used in the research of the tumor microenvironment.

BE2012, SR8278 derivative, is a potent and selective REV-ERBα/β Antagonist with EC50 values of 0.285 and 0.346 μM. BE2012 binds to the ligand-binding domain (LBD) of REV-ERB, preventing the receptor from recruiting co-inhibitory factors and thereby releasing the transcriptional repression on downstream target genes. BE2012 can upregulate the expression of myogenic transcription factors Myf5 and Myod, promoting muscle regeneration and repair in acute muscle injury micemodels.

BCX-5 (PD 141955) is an orally active inhibitor of purine nucleoside phosphorylase (PNP) with a Ki of 0.08 μM. BCX-5 can inhibit cell proliferation and mixed lymphocyte reaction. BCX-5 can increase plasma inosine and guanosine levels. BCX-5 can be used for the research of immunology.

BCR-ABL-IN-13 is a dual c-Src and Abl inhibitor, with a Ki value of 0.55 μM against c-Src, 0.10 μM against wild-type Abl, and 0.40 μM against the AblT315I mutant. BCR-ABL-IN-13 exerts competitive/mixed-type inhibitory effects on wild-type Abl, and non-competitive inhibitory effects on the drug-resistant AblT315I mutant. BCR-ABL-IN-13 can be used for the research of chronic myeloid leukemia.

Bcl-2-IN-24 (Compound 11g) is an efficient and selective Bcl-2 inhibitor with a Kd value of 11.3 μM. Bcl-2-IN-24 exhibits anti-proliferative activity against HCT-116 cells and A549 cells. Bcl-2-IN-24 effectively inhibits the colony-forming ability of tumor cells and induces cell apoptosis. Bcl-2-IN-24 can be used for research on colon cancer and lung cancer.

BC-3205 hydrochloride is an anti-amoeba agent. BC-3205 hydrochloride inhibits N. fowleri.

BBO-11818 is an orally active, highly selective (relative to NRAS and HRAS), non-covalent pan-KRAS inhibitor (IC50=28-120 nM). BBO-11818 specifically binds to the Switch-II/Helix 3 pocket, disrupts the KRAS:RAF1 interaction by inducing conformational changes, and blocks the MAPK signaling pathway. BBO-11818 exhibits significant anti-tumor activity, which not only inhibits cell proliferation and induces apoptosis, but also drives tumor regression in xenograft models. BBO-11818 produces synergistic effects when combined with Cetuximab, anti-PD-1 antibody or PI3Kα inhibitor. BBO-11818 is used in the research of KRAS mutation-related malignancies such as pancreatic cancer, non-small cell lung cancer and colorectal cancer.

BAY-Y 3118 hydrochloride is a quinolone antibacterial agent. BAY-Y 3118 hydrochloride has a broad antibacterial spectrum in vitro. BAY-Y 3118 hydrochloride exhibits high activity against gram-positive cocci and anaerobes. BAY-Y 3118 hydrochloride shows moderate activity against Enterobacteriaceae and Pseudomonas aeruginosa. BAY-Y 3118 hydrochloride can be used in the research of infectious diseases.

BAY-693 is a highly potent and highly selective ERK5 inhibitor with an IC50 of 6.40 μM. BAY-693 reduces the transcriptional activity of MEF2. BAY-693 is applicable for cancer research.

Barringtogenol C (Theasapogenol B) is one of seeds sapogenols of Thea sinensis L. Barringtogenol C is a type of barrigenol triterpenoid. Barringtogenol C derivatives exhibits antitumor activity.

BAA-065 is a selective and orally active PKMYT1 inhibitor with an IC50 of <50 nM. BAA-065 inhibits cancer cells proliferation, induces γH2AX expression and DNA damage. BAA-065 inhibits tumor growth in OVCAR3 xenograft mice. BAA-065 can be used for the research of cancer, such as ovarian cancer.

Aβ/tau aggregation-IN-4 (Compound D21) is an Aβ/tau aggregation inhibitor. Aβ/tau aggregation-IN-4 promotes the degradation of Aβ40/42 (Aβ40, IC50 = 2.151 μM; Aβ42, IC50 = 3.622 μM). Aβ/tau aggregation-IN-4 shows selective AChE inhibition (IC50: 5.56 μM). Aβ/tau aggregation-IN-4 inhibits MAO-A and MAO-B with IC50s of 0.59 μM and 0.09 μM, respectively. Aβ/tau aggregation-IN-4 suppresses intracellular ROS levels. Aβ/tau aggregation-IN-4 can be used in the research of Alzheimer's disease.

Aβ aggregation-IN-4 can alleviate the neurotoxicity of amyloid-β protein (Aβ) and significantly reduce the level of oligomeric complexes of Aβ (Aβ-OCs). Aβ aggregation-IN-4 does not decrease the level of amyloid-β protein (Aβ). Aβ aggregation-IN-4 attenuates Aβ oligomerization and prevents oligomer-induced death of primary cortical neurons. Aβ aggregation-IN-4 can be used for the study of Alzheimer’s disease (AD).